-
Mashup Score: 0'We need to see the data': FDA's Xeljanz safety warning stirs concerns for JAK inhibitors - 3 year(s) ago
For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years. In this latest alert regarding tofacitinib, the FDA warned providers of an increased risk for serious heart-related issues and cancer among older patients, compared with TNF inhibitors.This has left many experts anxious to dig into the full
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
The FDA issued an alert concerning an increased risk for serious cardiovascular events and malignancies with the JAK inhibitor, tofacitinib, compared with TNF inhibitors.
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet-
The @US_FDA warns of serious #cardiovascular events, cancer linked to Xeljanz. https://t.co/cVWwcNzNxH @CMichaelWhite2 #fda #Xeljanz #rheumatoidarthritis #fdawarning
-
-
Mashup Score: 2
The FDA issued an alert concerning an increased risk for serious cardiovascular events and malignancies with the JAK inhibitor, tofacitinib, compared with TNF inhibitors.
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet-
The @US_FDA warns of serious #cardiovascular events, cancer linked to Xeljanz. https://t.co/cVWwcNzNxH @CMichaelWhite2 #fda #Xeljanz #rheumatoidarthritis #fdawarning
-
-
Mashup Score: 0
The FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to tofacitinib compared with TNF inhibitors among older patients.As part of the alert, the FDA has recommended that health care professionals consider the benefits and risks associated with tofacitinib (Xeljanz, Pfizer) when making treatment decisions
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#FDA warns of heightened risk for #cardiac issues and #cancer after #Xeljanz falls short in safety study for #RheumatoidArthritis https://t.co/FZHRkR1asu
-
-
Mashup Score: 1No Xeljanz Plan Yet From FDA - 3 year(s) ago
Agency acknowledges negative safety study but not taking action at this point
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The FDA will await "further information" before making any moves to beef up label warnings or impose restrictions on #Xeljanz, the agency said. By @JohnGeverMPT. https://t.co/Roy4QYiuGp
-
-
Mashup Score: 0
The FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to tofacitinib compared with TNF inhibitors among older patients.As part of the alert, the FDA has recommended that health care professionals consider the benefits and risks associated with tofacitinib (Xeljanz, Pfizer) when making treatment decisions
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#FDA warns of increased risk for heart-related issues and #Cancer linked to #Xeljanz https://t.co/UF6k5o0Jq1 https://t.co/qABMC3lP3p
-
-
Mashup Score: 2
The FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to tofacitinib compared with TNF inhibitors among older patients.As part of the alert, the FDA has recommended that health care professionals consider the benefits and risks associated with tofacitinib (Xeljanz, Pfizer) when making treatment decisions
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The #FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to #tofacitinib / #Xeljanz compared with TNF inhibitors among older patients https://t.co/1lxcNS8DoG
-
-
Mashup Score: 0Methotrexate discontinuation feasible in patients with stable PsA receiving tofacitinib - 3 year(s) ago
Among patients with stable psoriatic arthritis receiving tofacitinib with methotrexate, some may be able to discontinue methotrexate without changes in disease activity or safety, according to data published in The Lancet Rheumatology.“Methotrexate is frequently used as a first-line treatment for psoriatic arthritis, and recommendations suggest that the optimal initial dose reaches 25
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Methotrexate discontinuation is feasible for patients with stable #psoriaticarthritis receiving #Xeljanz https://t.co/2IyGsnJRDd https://t.co/ej7eg93zU5
-
-
Mashup Score: 0
Patients with ankylosing spondylitis demonstrated rapid clinical response to tofacitinib, which produced significantly greater efficacy than placebo, but with more adverse events, according to a speaker at ACR Convergence 2020. “At week 16, the primary and type 1 error-controlled secondary efficacy endpoints were met, demonstrating significantly greater efficacy of tofacitinib 5 mg BID
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Xeljanz produced rapid clinical response in #ankylosingspondylitis patients, Dr. Atul Deodhar @OHSUNews noted in an #ACR20 late breaking abstract https://t.co/H9CQOzOTyH
-
-
Mashup Score: 0
The FDA has approved Xeljanz in tablet and oral formulations for the treatment of polyarticular course juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release from Pfizer. Previously approved in the United States for the treatment of adult patients with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis who had previously failed other
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The #FDA has approved #Xeljanz in tablet and oral formulations for the treatment of polyarticular course juvenile idiopathic #arthritis in patients aged 2 years and older, according to a press release from @pfizer https://t.co/iQ8xfLfqcl
-
Dr Kevin Winthrop @OHSUSOM and Dr Stanley Cohen @UTSWInternalMed weigh in on the latest #FDA warning regarding #Xeljanz, what it means for JAK inhibitors as a class, and the problems with "living by press release" https://t.co/yxwFfZsKOD